Donna Lam Cahill, PA-C, outlines the psychosocial burdens of vitiligo, emphasizing that a patient’s disease burden does not always correlate directly with the amount of skin affected. To contextualize treatment timelines, she shares efficacy data from the TRuE-V studies evaluating ruxolitinib cream over the course of up to two years. The findings highlight that total body repigmentation significantly improves with extended use, showing that 51% of continuous users achieved a 50% improvement by year one and 64% by year two. Ultimately, she advises clinicians to tailor expectations, support patients through the lengthy treatment journey, and connect them with community resources like VIT Friends.
Topics Covered
- The psychosocial impact of vitiligo
- TRuE-V trial data on ruxolitinib
- Clinical management and expectations in patients with vitiligo
